{"id":83961,"date":"2022-08-31T08:52:56","date_gmt":"2022-08-31T12:52:56","guid":{"rendered":"https:\/\/newsroom.carleton.ca\/?p=83961"},"modified":"2025-08-19T09:36:19","modified_gmt":"2025-08-19T13:36:19","slug":"carleton-university-and-turnstone-biologics-extend-partnership-for-research-and-training-in-biosciences","status":"publish","type":"post","link":"https:\/\/carleton.ca\/news\/2022\/carleton-university-and-turnstone-biologics-extend-partnership-for-research-and-training-in-biosciences\/","title":{"rendered":"Carleton University and Turnstone Biologics Extend partnership for Research and Training in Biosciences"},"content":{"rendered":"\n
\n
\n\n
\n
\n
\n

\n Carleton University and Turnstone Biologics Extend partnership for Research and Training in Biosciences\n <\/h1>\n \n \n <\/header>\n\n <\/div>\n\n <\/div>\n\n <\/div>\n<\/section>\n\n

Carleton University today announced the extension of its partnership with Turnstone Biologics (\u201cTurnstone\u201d), a clinical-stage biotechnology company developing next-generation immunotherapies to treat and cure solid tumours. The partnership, renewed for a second term, further supports Carleton\u2019s growing biosciences programs and the development of scientific talent, and augments the university\u2019s expertise in novel oncology research.<\/p>\n\n\n\n

\u201cThis is an opportune time to extend our partnership with Turnstone as we prepare to launch our Life Sciences 2030 Plan,\u201d said Maria DeRosa, PhD, Dean of Science and Professor in the Department of Chemistry and the Institute of Biochemistry, Carleton University. \u201cOur vision of positioning Carleton as the premier Canadian post-secondary institution for training, talent development and research in the life sciences sector is significantly enhanced through our innovative and productive relationship with Turnstone.\u201d<\/p>\n\n\n\n

Since 2019, Turnstone has conducted internal development work and sponsored research at Carleton University. The research being undertaken at Carleton includes generating new insights into how cancer therapies regulate immune cells and their effects on new candidate treatments, and how viruses and environmental toxins contribute to the development of chronic diseases. Additionally, representatives of Turnstone have mentored students and participated in life sciences events on campus.<\/p>\n\n\n\n

\u201cCarleton University offers a wonderful and vibrant academic community. The partnership with Carleton allows us to interact with a variety of excellent researchers and promising students to create opportunities to collaborate, foster scientific ideas and invest in the brilliant minds of the future,\u201d said David Stojdl, PhD, Scientific Co-Founder, Senior Vice President and Senior Scientific Fellow, Turnstone Biologics.<\/p>\n\n\n\n

The extension of the partnership enables Turnstone to continue engaging graduate students and to provide them with support to conduct research in the areas of immunology, microbiology, biochemistry, biotechnology and bioinformatics. The partnership promotes integration with students through Work-Integrated Learning (WIL), job shadowing and experiential education. Graduates will also have the opportunity to closely interact with Turnstone\u2019s researchers to receive guidance and mentorship.<\/p>\n\n\n\n

\u201cTalent development is a key objective of this exciting and mutually beneficial research partnership. Together through our partnership, Carleton University and Turnstone are preparing the next generation of life sciences researchers to continue advancing immunotherapies with the aim of improving the survival rate of people with cancer,\u201d said Rafik Goubran, PhD, Vice-President (Research and International) and Chancellor\u2019s Professor, Carleton University.<\/p>\n\n\n\n

About Carleton University<\/strong><\/p>\n\n\n\n

Carleton is a dynamic, research-intensive institution that engages in partnerships to address the world\u2019s most pressing issues. The university\u2019s corporate collaborations bring together world-class companies, researchers and a new generation of talent with 32,000 students to deliver innovations and results that are driving a more prosperous, sustainable future.<\/p>\n\n\n\n

About Turnstone Biologics<\/strong><\/p>\n\n\n\n

Turnstone Biologics, a clinical stage biotechnology company, is developing new medicines to treat and cure solid tumours by pioneering differentiated approaches with two clinically-validated technologies, tumour infiltrating lymphocyte (\u201cTIL\u201d) therapy and viral immunotherapy. Turnstone\u2019s innovative TIL therapy, which is designed to extend the efficacy of TILs to multiple solid tumour indications by selecting and manufacturing the most potent tumour-reactive T-cells (\u201cSelected TILs\u201d) for tumour eradication, represents the Company\u2019s foundational therapeutic modality driving its cancer immunotherapy pipeline. The Company\u2019s lead Selected TIL therapy candidate, TIDAL-01, is expected to enter clinical trials in 2022. Turnstone is developing additional strategies to further potentiate the clinical benefit of Selected TILs, including use in combination with their novel viral immunotherapy.<\/p>\n\n\n\n

For more information, please visit www.turnstonebio.com<\/a>, and follow Turnstone on LinkedIn<\/a>.<\/p>\n\n\n\n

Media Contact
\n<\/strong>Steven Reid (he\/him)
\nMedia Relations Officer
\nCarleton University
\n613-265-6613
\nSteven.Reid3@carleton.ca<\/a><\/p>\n\n\n\n

Follow us on Twitter: www.twitter.com\/Cunewsroom<\/a>
\nCOVID 19 Updates: https:\/\/newsroom.carleton.ca\/coronavirus-covid-19\/messages\/<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Carleton University today announced the extension of its partnership with Turnstone Biologics (\u201cTurnstone\u201d), a clinical-stage biotechnology company developing next-generation immunotherapies to treat and cure solid tumours. The partnership, renewed for a second term, further supports Carleton\u2019s growing biosciences programs and the development of scientific talent, and augments the university\u2019s expertise in novel oncology research. \u201cThis […]<\/p>\n","protected":false},"author":410,"featured_media":80049,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[1],"tags":[1559,160,139,91],"class_list":["post-83961","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-releases","tag-advancement","tag-chemistry","tag-partnerships","tag-research"],"acf":{"cu_post_thumbnail":false},"_links":{"self":[{"href":"https:\/\/carleton.ca\/news\/wp-json\/wp\/v2\/posts\/83961","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/carleton.ca\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/carleton.ca\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/carleton.ca\/news\/wp-json\/wp\/v2\/users\/410"}],"replies":[{"embeddable":true,"href":"https:\/\/carleton.ca\/news\/wp-json\/wp\/v2\/comments?post=83961"}],"version-history":[{"count":2,"href":"https:\/\/carleton.ca\/news\/wp-json\/wp\/v2\/posts\/83961\/revisions"}],"predecessor-version":[{"id":83963,"href":"https:\/\/carleton.ca\/news\/wp-json\/wp\/v2\/posts\/83961\/revisions\/83963"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/carleton.ca\/news\/wp-json\/wp\/v2\/media\/80049"}],"wp:attachment":[{"href":"https:\/\/carleton.ca\/news\/wp-json\/wp\/v2\/media?parent=83961"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/carleton.ca\/news\/wp-json\/wp\/v2\/categories?post=83961"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/carleton.ca\/news\/wp-json\/wp\/v2\/tags?post=83961"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}